» Articles » PMID: 21087859

Antitumor Agents 281. Design, Synthesis, and Biological Activity of Substituted 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one Analogs (ATBO) As Potent in Vitro Anticancer Agents

Overview
Specialty Biochemistry
Date 2010 Nov 20
PMID 21087859
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

In our exploration of new biologically active chemical entities, we designed and synthesized a novel class of antitumor agents, substituted 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (ATBO) analogs. We evaluated their cytotoxic activity against seven human tumor cell lines from different tissues, and established preliminary structure-activity relationships (SAR). All analogs, except 8, 9, and 25-27, displayed potent tumor cell growth inhibitory activity. Especially, compounds 15 and 33 with a 4-methoxyphenyl group at position C-4 were extremely potent with ED(50) values of 0.008-0.064 and 0.035-0.32 μM, respectively. Compound 15 was the most potent analog compared with structurally related neo-tanshinlactone (e.g., 1) and 4-amino-2H-benzo[h]chromen-2-one (ABO, e.g., 4) analogs, and thus merits further exploration as an anti-cancer drug candidate.

Citing Articles

Recent Progress of Research on Herbal Products Used in Traditional Chinese Medicine: the Herbs belonging to The Divine Husbandman's Herbal Foundation Canon ( Shén Nóng Běn Cǎo Jīng).

Lee K, Morris-Natschke S, Qian K, Dong Y, Yang X, Zhou T J Tradit Complement Med. 2014; 2(1):6-26.

PMID: 24716110 PMC: 3943012. DOI: 10.1016/s2225-4110(16)30066-9.


Antitumor agents 287. Substituted 4-amino-2H-pyran-2-one (APO) analogs reveal a new scaffold from neo-tanshinlactone with in vitro anticancer activity.

Dong Y, Nakagawa-Goto K, Lai C, Morris-Natschke S, Bastow K, Lee K Bioorg Med Chem Lett. 2011; 21(8):2341-4.

PMID: 21420855 PMC: 3072684. DOI: 10.1016/j.bmcl.2011.02.084.

References
1.
Kim D, Dong C, Kim J, Guo H, Huang J, Tiseni P . New syntheses of E7389 C14-C35 and halichondrin C14-C38 building blocks: double-inversion approach. J Am Chem Soc. 2009; 131(43):15636-41. DOI: 10.1021/ja9058475. View

2.
Crommelin D, Stolk P, Besancon L, Shah V, Midha K, Leufkens H . Pharmaceutical sciences in 2020. Nat Rev Drug Discov. 2010; 9(2):99-100. DOI: 10.1038/nrd3087. View

3.
Wang X, Nakagawa-Goto K, Bastow K, Don M, Lin Y, Wu T . Antitumor agents. 254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents. J Med Chem. 2006; 49(18):5631-4. DOI: 10.1021/jm060184d. View

4.
Vallance P, Williams P, Dollery C . The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Clin Pharmacol Ther. 2010; 87(5):525-7. DOI: 10.1038/clpt.2010.29. View

5.
Dong Y, Shi Q, Liu Y, Wang X, Bastow K, Lee K . Antitumor agents. 266. Design, synthesis, and biological evaluation of novel 2-(furan-2-yl)naphthalen-1-ol derivatives as potent and selective antibreast cancer agents. J Med Chem. 2009; 52(11):3586-90. PMC: 2754228. DOI: 10.1021/jm9001567. View